U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H30N6O4S
Molecular Weight 474.5783
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SILDENAFIL

SMILES

CCCc1c2c(c(=O)[nH]c(-c3cc(ccc3OCC)S(=O)(=O)N4CCN(C)CC4)n2)n(C)n1

InChI

InChIKey=BNRNXUUZRGQAQC-UHFFFAOYSA-N
InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)

HIDE SMILES / InChI
Sildenafil (Viagra, Revatio) is a PDE5 inhibitor which was approved by FDA for the treatment of erectile disfunction and adults with pulmonary arterial hypertension. Upon administration sildenafil inhibits PDE5 and results in elevated level of cyclic guanosine monophosphate and smooth muscle relaxation.

CNS Activity

Curator's Comment:: CNS activity was observed on rats.

Originator

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
VIAGRA

Approved Use

VIAGRA is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.

Launch Date

890956800000
Primary
REVATIO

Approved Use

REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening.

Launch Date

1117756800000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
159 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
530 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.07 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SILDENAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources:
healthy, 33
Health Status: healthy
Age Group: 33
Sex: M
Sources:
Disc. AE: Flushing, Headache...
AEs leading to
discontinuation/dose reduction:
Flushing
Headache
Tachycardia (mild)
Sources:
2400 mg single, oral
Overdose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy, 33
Health Status: healthy
Age Group: 33
Sex: M
Sources:
Disc. AE: Visual field defect...
AEs leading to
discontinuation/dose reduction:
Visual field defect
Sources:
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources:
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: M
Sources:
Disc. AE: Rhabdomyolysis, Visual disturbance NOS...
AEs leading to
discontinuation/dose reduction:
Rhabdomyolysis
Visual disturbance NOS
Sources:
80 mg 3 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: multiple
Dose: 80 mg, 3 times / day
Sources:
unhealthy, 47.5
Health Status: unhealthy
Age Group: 47.5
Sex: M+F
Sources:
6.5 g single, oral
Overdose
Dose: 6.5 g
Route: oral
Route: single
Dose: 6.5 g
Sources:
healthy, 56
Health Status: healthy
Age Group: 56
Sex: M
Sources:
Disc. AE: Vomiting, Blurred vision...
AEs leading to
discontinuation/dose reduction:
Vomiting (severe)
Blurred vision
Sinus tachycardia
Sources:
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 56
Disc. AE: Cardiomegaly, Fibrosis myocardial...
AEs leading to
discontinuation/dose reduction:
Cardiomegaly (grade 5)
Fibrosis myocardial (grade 5)
Sources:
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 58
Health Status: unhealthy
Age Group: 58
Sex: M
Sources:
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (0.32%)
Vomiting (0.32%)
Leg pain (0.32%)
Backache (0.32%)
Intermittent headache (0.32%)
Dyspepsia (0.32%)
Headache (0.32%)
Sources:
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M
Sources:
Disc. AE: Headache, Flushing...
AEs leading to
discontinuation/dose reduction:
Headache (0.61%)
Flushing (0.61%)
Sources:
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M
Sources:
Disc. AE: Headache, Flushing...
AEs leading to
discontinuation/dose reduction:
Headache (0.9%)
Flushing (0.44%)
Blurred vision (0.44%)
Groin pain (1.3%)
Sources:
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
unhealthy, 67
Health Status: unhealthy
Age Group: 67
Sex: M
Sources:
Disc. AE: Acute kidney injury...
AEs leading to
discontinuation/dose reduction:
Acute kidney injury
Sources:
AEs

AEs

AESignificanceDosePopulation
Flushing Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources:
healthy, 33
Health Status: healthy
Age Group: 33
Sex: M
Sources:
Headache Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources:
healthy, 33
Health Status: healthy
Age Group: 33
Sex: M
Sources:
Tachycardia mild
Disc. AE
2000 mg single, oral
Overdose
Dose: 2000 mg
Route: oral
Route: single
Dose: 2000 mg
Sources:
healthy, 33
Health Status: healthy
Age Group: 33
Sex: M
Sources:
Visual field defect Disc. AE
2400 mg single, oral
Overdose
Dose: 2400 mg
Route: oral
Route: single
Dose: 2400 mg
Sources:
healthy, 33
Health Status: healthy
Age Group: 33
Sex: M
Sources:
Rhabdomyolysis Disc. AE
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources:
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: M
Sources:
Visual disturbance NOS Disc. AE
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Sources:
unhealthy, 45
Health Status: unhealthy
Age Group: 45
Sex: M
Sources:
Blurred vision Disc. AE
6.5 g single, oral
Overdose
Dose: 6.5 g
Route: oral
Route: single
Dose: 6.5 g
Sources:
healthy, 56
Health Status: healthy
Age Group: 56
Sex: M
Sources:
Sinus tachycardia Disc. AE
6.5 g single, oral
Overdose
Dose: 6.5 g
Route: oral
Route: single
Dose: 6.5 g
Sources:
healthy, 56
Health Status: healthy
Age Group: 56
Sex: M
Sources:
Vomiting severe
Disc. AE
6.5 g single, oral
Overdose
Dose: 6.5 g
Route: oral
Route: single
Dose: 6.5 g
Sources:
healthy, 56
Health Status: healthy
Age Group: 56
Sex: M
Sources:
Cardiomegaly grade 5
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 56
Fibrosis myocardial grade 5
Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources:
healthy, 56
Backache 0.32%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 58
Health Status: unhealthy
Age Group: 58
Sex: M
Sources:
Dyspepsia 0.32%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 58
Health Status: unhealthy
Age Group: 58
Sex: M
Sources:
Headache 0.32%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 58
Health Status: unhealthy
Age Group: 58
Sex: M
Sources:
Intermittent headache 0.32%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 58
Health Status: unhealthy
Age Group: 58
Sex: M
Sources:
Leg pain 0.32%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 58
Health Status: unhealthy
Age Group: 58
Sex: M
Sources:
Nausea 0.32%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 58
Health Status: unhealthy
Age Group: 58
Sex: M
Sources:
Vomiting 0.32%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 58
Health Status: unhealthy
Age Group: 58
Sex: M
Sources:
Flushing 0.61%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M
Sources:
Headache 0.61%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M
Sources:
Blurred vision 0.44%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M
Sources:
Flushing 0.44%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M
Sources:
Headache 0.9%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M
Sources:
Groin pain 1.3%
Disc. AE
100 mg 1 times / day multiple, oral
Recommended
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
unhealthy, 60
Health Status: unhealthy
Age Group: 60
Sex: M
Sources:
Acute kidney injury Disc. AE
400 mg single, oral
Overdose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
unhealthy, 67
Health Status: unhealthy
Age Group: 67
Sex: M
Sources:
PubMed

PubMed

TitleDatePubMed
Phenelzine-induced sexual dysfunction treated with sildenafil.
1999 Apr-Jun
Sildenafil in the treatment of female sexual dysfunction induced by selective serotonin reuptake inhibitors.
1999 Jun
Acute myocardial infarction following sildenafil citrate (Viagra) intake in a nitrate-free patient.
1999 Nov
Sildenafil and erectile dysfunction.
2000 Dec
Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy.
2000 Jul
Alpha-adrenergic receptor blockade by phentolamine increases the efficacy of vasodilators in penile corpus cavernosum.
2000 Mar
Acute myocardial infarction associated wiht Sildenafil (Viagra) ingestion.
2000 May
[Myocardial ischemia after administration de sildenafil: description of a case and review of the literature].
2000 Sep
A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction.
2001
Use of sildenafil in penile implant patients.
2001
Safe use of sildenafil in patients with coronary artery disease.
2001 Apr
Cost-sharing for prescriptions of sildenafil and finasteride: a case study in veteran patients.
2001 Apr
Sildenafil citrate for penile hemodynamic determination: an alternative to intracavernosal agents in Doppler ultrasound evaluation of erectile dysfunction.
2001 Apr
Characterization of TbPDE2A, a novel cyclic nucleotide-specific phosphodiesterase from the protozoan parasite Trypanosoma brucei.
2001 Apr 13
Studies of Viagra offer some reassurance to men with concerns about cardiac effects.
2001 Apr 18
Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction.
2001 Feb
Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials.
2001 Feb
Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications.
2001 Feb
Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction.
2001 Feb
Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis.
2001 Feb
Sildenafil modulates hemodynamics and pulmonary gas exchange.
2001 Feb
Should male patients with chest pain be questioned about Viagra use during triage screening?
2001 Feb
Sex and the heart: what is the role of the cardiologist?
2001 Feb
Are things looking up for the treatment of gastroparesis? Sildenafil in animal models of diabetic gastropathy.
2001 Feb
Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase.
2001 Feb
Sildenafil inhibits gastroduodenal motility.
2001 Feb
Sildenafil-simvastatin interaction: possible cause of rhabdomyolysis?
2001 Feb 15
Cost-effectiveness of sildenafil.
2001 Feb 6
The role of nitric oxide in penile erection.
2001 Jan
Intracavernosal injection therapy. Does it still have a role in erectile dysfunction?
2001 Jan
Sexual aspects of headache. How sexual function relates to headaches and their causes and treatment.
2001 Jan
Viagra: are anaesthetists rising to the challenge?
2001 Jan
Practice patterns in the diagnosis and treatment of erectile dysfunction among family practice physicians.
2001 Jan
Preliminary observations of sildenafil treatment for erectile dysfunction in dialysis patients.
2001 Jan
"cAMP-specific" phosphodiesterase contributes to cGMP degradation in cerebellar cells exposed to nitric oxide.
2001 Jan
[Prescribing of sildenafil by national insurance program physicians. What basic sexual medicine qualification is required?].
2001 Jan 11
[Erectile dysfunction in coronary heart disease. No fear about the blue pill].
2001 Jan 18
Effect of sildenafil on non-adrenergic non-cholinergic neurotransmission in bovine penile small arteries.
2001 Jan 26
Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site.
2001 Jan 26
Identification and regulation of human PDE5A gene promoter.
2001 Jan 26
Initial uptake in use of sildenafil in general practice.
2001 Mar
Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
2001 Mar
Comparison of FDA reports of patient deaths associated with sildenafil and with injectable alprostadil.
2001 Mar
Clinical efficacy of sildenafil in patients on chronic dialysis.
2001 Mar
Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England.
2001 Mar 17
Patents

Sample Use Guides

Erectile disfunction: For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. Pulmonary arterial hypertension: 5 mg or 20 mg three times a day, 46 hours apart (oral); 2.5 mg or 10 mg three times a day administered as an intravenous bolus injection.
Route of Administration: Other
In Vitro Use Guide
Sources: www.ncbi.nlm.nih.gov/pubmed/20590607
Human bladder samples were treated with sildenafil (10 nM–30 µM) to test the ability of the drug to inhibit contraction.
Name Type Language
SILDENAFIL
EMA EPAR   HSDB   INN   MI   VANDF   WHO-DD  
INN  
Official Name English
SILDENAFIL [VANDF]
Common Name English
SILDENAFIL RATIOPHARM
Brand Name English
APHRODIL
Brand Name English
HIP-0908
Code English
VIZARSIN
Brand Name English
PIPERAZINE, 1-((3-(6,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO(4,3-D)PYRIMIDIN-5-YL)-4-ETHOXYPHENYL)SULFONYL)-4-METHYL-
Systematic Name English
SILDENAFIL [MI]
Common Name English
HIP0908
Code English
SILDENAFIL [EMA EPAR]
Common Name English
SILDENAFIL [WHO-DD]
Common Name English
SILDENAFIL ACTAVIS
Brand Name English
1-((3-(6,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO(4,3-D)PYRIMIDIN-5-YL)-4-ETHOXYPHENYL)SULFONYL)-4-METHYLPIPERAZINE
Systematic Name English
SILDENAFIL [HSDB]
Common Name English
SILDENAFIL TEVA
Brand Name English
PATREX
Brand Name English
SILDENAFIL [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2127
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS VIZARSIN (AUTHORIZED: ERECTILE DYSFUNCTION)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS REVATIO (AUTHORIZED: HYPERTENSION, PULMONARY)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
WHO-VATC QG04BE03
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS VIAGRA (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
NDF-RT N0000175599
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
NDF-RT N0000020026
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS SILDENAFIL RATIOPHARM (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS PATREX (WITHDRAWN: ERECTILE DYSFUNCTIONS)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS SILDENAFIL ACTAVIS (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
FDA ORPHAN DRUG 344211
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EMA ASSESSMENT REPORTS SILDENAFIL TEVA (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
WHO-ATC G04BE03
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
EU-Orphan Drug EU/3/17/1885
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
LIVERTOX 885
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
Code System Code Type Description
WIKIPEDIA
SILDENAFIL
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
EVMPD
SUB10517MIG
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
NCI_THESAURUS
C61940
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
DRUG CENTRAL
2441
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
FDA UNII
3M7OB98Y7H
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
CAS
139755-83-2
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
RXCUI
136411
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY RxNorm
ChEMBL
CHEMBL192
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
PUBCHEM
135398744
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
INN
7374
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
HSDB
7305
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
IUPHAR
4743
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
MESH
C101426
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
EPA CompTox
139755-83-2
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
MERCK INDEX
M9898
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY Merck Index
LACTMED
Sildenafil
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY
DRUG BANK
DB00203
Created by admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
PRIMARY